NEW YORK, Jan. 2, 2026 — Hoth Therapeutics (NASDAQ: HOTH) announced the filing of two U.S. provisional patent applications that expand the company’s intellectual property and establish an oncology-focused dermatology platform to address treatment-induced skin toxicity from modern cancer therapies.
One provisional application covers the topical treatment of radiation-induced skin toxicity in oncology patients. The second targets dermatologic toxicities associated with emerging targeted cancer therapies, including second- and third-generation menin inhibitors.
Together, the filings secure priority rights for the use of HT-001 to treat dermatologic toxicities across multiple oncology modalities, including radiation therapy and next-generation targeted agents. As cancer therapies become more effective and patients remain on treatment longer, management of treatment-limiting skin toxicities has become a growing unmet need in oncology care.
Radiotherapy-induced dermatitis and dermatologic adverse effects from targeted therapies can cause pain, inflammation, severe pruritus, infection risk, reduced quality of life, and interruptions or discontinuations of cancer treatment. Current options are largely supportive, with few mechanism-driven therapies that address the underlying biological drivers of these conditions.
Hoth says the patent filings protect the use of HT-001, a receptor antagonist with an established pharmacologic profile, to target neurogenic and inflammatory pathways implicated in therapy-induced skin injury. The company believes the approach may represent a novel, potentially first-in-class strategy within the oncology supportive-care and oncodermatology markets.
“These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care,” said Robb Knie of Hoth Therapeutics. “As cancer therapies advance, the ability to manage treatment-related toxicities is becoming essential. We believe this emerging platform highlights our strategy of identifying differentiated, mechanism-driven opportunities that can address significant unmet needs while creating long-term shareholder value.”
Hoth said the provisional patents support development of a scalable oncology-adjacent platform with potential applications across radiation oncology, targeted cancer therapies, dermatology, and inflammatory skin disorders, and provide flexibility for additional preclinical development, formulation optimization, and future U.S. and international patent protection.
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to improve patient quality of life. More information is available at https://ir.hoththerapeutics.com/.
Leave a Reply